Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types

NCT05107674 is registered in ClinicalTrials.gov with Nurix Therapeutics, Inc. as lead sponsor.

NCT NCT05107674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05107674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types
Lead sponsor
Nurix Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
September 29, 2021
Completion date
February 28, 2028
Enrollment
345 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, diffuse large b cell lymphoma (dlbcl), gastric cancer, gastroesophageal junction (gej) cancer, head and neck squamous cell carcinoma, malignant pleural mesothelioma (mpm), metastatic castration-resistant prostate cancer (mcrpc), metastatic or unresectable melanoma, metastatic urothelial carcinoma, microsatellite stable colorectal carcinoma, non-small cell lung cancer (nsclc), ovarian cancer, epithelial, richter transformation, triple negative breast cancer (tnbc)